Home > Result Summaries: Compounds > fluticasone furoate/vilanterol

Result Summaries: fluticasone furoate/vilanterol

GSK Study ID	Phase	Title	Summary (Download)
102934	phase 1	An open-label, non-randomised, three-way crossover, single dose study to determine the absolute bioavailability of fluticasone furoate (FF)/GW642444 Inhalation Powder, in healthy subjects (0 citation(s))
106827	phase 3	HZA106827: A randomised, double-blind, placebo-controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents (0 citation(s))
106829	phase 3	HZA106829: A randomised, double-blind, parallel group, multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder, Fluticasone Furoate Inhalation Powder alone, and Fluticasone Propionate alone in the treatment of persistent asthma in adults and adolescents (0 citation(s))
106837	phase 3	A Long-Term, Randomized, Double-Blind, Parallel Group Study of Fluticasone Furoate/GW642444 Inhalation Powder Once-Daily and Fluticasone Furoate Inhalation Powder Once-Daily in Subjects with Asthma (0 citation(s))
106839	phase 3	A Randomized, Double-Blind, Double Dummy, Active Comparator, Parallel Group, Multicenter Study to Evaluate the Safety of Once-Daily Fluticasone Furoate/GW642444 Inhalation Powder for 52 Weeks in Adolescent and Adult Subjects with Asthma (0 citation(s))
106851	phase 3	Study HZA106851: A Study of the Effects of Inhaled Fluticasone Furoate/GW642444 versus Placebo on the HPA Axis of Adolescent and Adult Asthmatics (0 citation(s))
113091	phase 3	A randomised, double-blind, double-dummy, parallel-group multicentre study to assess efficacy and safety of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Propionate/Salmeterol Inhalation Powder in the treatment of persistent asthma in adults and adolescents (0 citation(s))
113405	phase 4	Special Drug Use Investigation for ADOAIR Metered-dose Inhaler (Pediatric) (0 citation(s))
115247	phase 3	A 12week study to evaluate the effect of fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) 100/25 mcg Inhalation Powder delivered once daily via a Novel Dry Powder Inhaler (NDPI) on arterial stiffness compared with Tiotropium bromide 18 mcg delivered once daily via a HandiHaler in subjects with chronic obstructive pulmonary disease (COPD). (0 citation(s))
115354	n\a	PGx411:Evaluation of the Genetic Contribution (efficacy) to the Steroid Response in studies FFA109684, FFA109685 and FFA109687 (0 citation(s))
116706	n\a	Pooled analysis of the assessment of the association of lung function improvements on COPD related exacerbations and other endpoints (0 citation(s))